(secondQuint)SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI).

 ECOSPOR is a Phase 2, multicenter, randomized, double blind, placebo controlled clinical study with 2 treatment arms (SER-109 or placebo).

 Patients who have diarrhea and a positive C.

 difficile test result on a stool sample, and who have responded to standard of care antibiotic treatment will receive study drug on Day 1.

 Those patients who experience a recurrence of CDI up to 8 weeks after SER 109 or placebo treatment will be offered an opportunity to enroll in an open label SER 109 extension study (Study SERES 005).

.

 SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)@highlight

The study will involve administering the study drug as a single dose of study drug or placebo.

 This study is designed to demonstrate the superiority of the experimental drug versus placebo in adult patients with recurrent CDI.

